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Summary We have studied the cytotoxic effects of recombinant tumour necrosis factor and recombinant
gamma interferon on primary cultures of leukaemia cells. The agents were added alone or in a combination to
cells from 17 patients. Eleven had acute myeloblastic leukaemia (6 at presentation, 5 at relapse), 4 had acute
lymphoblastic leukaemia, one had hairy cell leukaemia, and 2 had chronic myeloid leukaemia - one of whom
was in myeloid blast transformation. Cells from patients with lymphoid malignancies or from the patient with
chronic phase CML were not affected by either agent in any dose combination. In contrast, reduction of
viability of myeloid blasts was weakly accelerated by TNF and y-interferon individually. Combination of the
agents invariably produced enhanced killing and additive or synergistic effects were seen when 20-500IUml- I
of each cytokine was present. This sensitivity was also shown by blast cells from 5 patients with relapsed
AML. We therefore suggest that trials of such combination therapy may be indicated in drug resistant or
relapsed AML.
Two cytokines, tumour necrosis factor (TNF) and y-
interferon (y-IFN), have been frequently suggested as
therapeutic agents for the treatment of malignant disease.
TNF was first characterised as a product from activated
macrophages that induced regression of some transplanted
tumours in rodents (Carswell et al., 1975; Ruff et al., 1980)
while having little or no effect on primary cell cultures or
normal cell lines. A material with similar properties,
lymphotoxin, was obtained from mitogen stimulated
lymphocytes (Ruddle et al., 1968; Granger et al., 1968) and
both agents have subsequently been cloned from human cell
lines (Pennica et al., 1984; Gray et al., 1984). It is now clear
that in addition to its cytotoxic effects on malignant cells,
TNF also regulates the growth of many normal cells -
including haemopoietic precursors - by producing reversible
suppression of some specific cellular proteins at the level of
transcription (Beutler et al., 1985a,b) and by increasing
production of others (Kohase et al., 1986). Although TNF
effectively destroys some tumour derived lines, others are
almost entirely insensitive, and it has been postulated that
lack of susceptibility may correlate with low level or absent
expression of specific TNF receptors (Tsujimoto et al., 1986;
Ruggiero et al., 1986).
Gamma-IFN, like TNF, regulates the growth and
differentiation of both normal and malignant cells: it acts to
increase synthesis and expression of some proteins, while
inhibiting production of others. Although y-IFN alone
inhibits the growth of certain tumours in vitro, its therapeutic
effects as a single agent have generally been disappointing
(Hawkins, 1986; Bonnem & Spiegel, 1986). However, one of
the proteins often induced by y-IFN is the receptor for TNF,
and it has been observed that cell lines with few TNF
receptors and which are TNF-insensitive may express
increased numbers of TNF receptors and become susceptible
to this cytokine when y-IFN is also present in the culture
(Tsujimoto et al., 1986; Ruggiero et al., 1986).
We have now investigated the susceptibility of acute
leukaemia blast cells to TNF and y-IFN alone or in
combination. We show that lymphoid leukaemias are
generally unaffected by these cytokines, but that myeloid
blast cells, including those obtained from patients in relapse,
may be highly susceptible to the combination of TNF and y-
IFN, while showing little response to either agent alone. As
these cytokines have a mode of action distinct from
conventional chemotherapeutic agents, these observations
suggest that combination therapy with TNF and y-IFN
should be evaluated in vivo for the treatment of relapsed or
resistant myeloid leukaemia.
Materials and methods
Patients and sample collection
Peripheral blood samples from patients with leukaemia were
collected in preservative-free heparin. Eighteen patients were
studied. Four had ALL, (3 common, 1 T cell), 1 had hairy
cell leukaemia and 11 had AML (8 FAB Ml or 2, 1 FAB
M4) of whom 6 were untreated and 5 had relapsed after
treatment with daunorubicin, cytosine arabinoside and
thioguanine. There were 2 patients with CGL, one in first
chronic phase (CGL-CP) and 1 with myeloid blast crisis
(CGL-BC). Mononuclear cells were isolated by separation
over Lymphoprep (Nyegaard) at 400g for 25min. All acute
leukaemia samples studied had >90% blast cells.
Culture conditions
Cells were grown in RPMI 1640 supplemented with 10%
foetal calf serum (FCS), 1-glutamine (2mM), penicillin
(1OOIUml-1) and streptomycin (100pgml-1) at 380C in
7.5% C02, and were cultured in 96 well flat bottom Nunc
microculture plates at 2 x 105 cells/I00 p1.
Cytokines
Recombinant tumour necrosis factor (TNF) (derived
originally from a human monocyte cell line and expressed in
E.Coli), specific activity 1.5 x 10 IUmg- 1 (gift of BASF
Knoll, W. Germany) and recombinant (E.Coli) y-Interferon,
specific activity 2.2 x 107 IU mg - (y-IFN gift of Biogen SA,
Geneva, Switzerland) were diluted in culture medium and
added at concentrations of 20-2000 Uml- in a
chequerboard pattern (see figure 1). Each combination of
cytokines was added to duplicate wells. Cytotoxicity was
determined on days 3, 5 and 7 or on days 4 and 7.
Effects ofcytokines
Cells from each well were enumerated using a Coulter ZF
electronic counter. Cell viability was determined by mixing
cells 1:1 (v/v) with 0.5% (w/v) Nigrosin (Sigma) containing
1% (w/v) Fast Green (Sigma). After ten minutes at room
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temperature the cells from individual wells were cyto-
centrifuged onto slides, air dried and fixed with acetone-free
methanol beforecounterstaining withMay-Grunwald/Giesma.
Two hundred cells were counted on each slide. In preliminary
experiments this technique compared well in sensitivity to
trypan blue exclusion and had the advantage that the
morphology of viable cells could be assessed (Bird et al.,
1985).
Statistical analysis
Comparison between the effects of different treatments was
made by analysis of variance.
Results
Cells from all 5 patients with lymphoid malignancies and
from the patient with CGL-CP showed no response to the
agents alone or in combination. In contrast cells from all 11
patients with AML and from the patient with CGL-BC
showed significant responses. Although reduction in viability
of AML blasts with time occurred in control cultures, this
was only weakly accelerated in the presence of either TNF
or y-IFN alone. However, the combination of TNF and y-
IFN was invariably more effective at inducing cell death.
Four patient samples were extremely sensitive and showed
between 0 and 5% survival of cells at days 5-7 while control
culture viability ranged from 60-90%; even in the least
susceptible patient, cell survival was only 34% in the
presence of TNF and y-IFN. Figure la,b shows the dose-
response effects at day 5 of culture using data from the most
susceptible (Figure la) and the least susceptible (Figure lb)
cells. y-IFN alone produced a small but significant effect on
viability, while TNF had little effect. At doses between 20
and 200U of both agents, however, synergy was apparent
and this was maximal at 50OUml- . Figure 2a,b shows the
time course of cell death in these patients, using 500Uml-1
of TNF and y-IFN. Cell killing was most rapid in the first
48-96h but continued to increase up to the 7th day of study.
Figure 3 pools data from all 12 patients with AML and
compares the mean cell survival between the different
treatment groups. Combination therapy in vitro with y-IFN
and TNF clearly has a highly significant effect compared
with no treatment (P<0.0001) or with addition of either
agent alone (P<0.001).
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Figure 2a,b Time course of cell death of blast cells from good
(a) and poor (b) responder illustrated in Figure la, b,
demonstrating viability of untreated cells and of cells treated
with 50OUTNF and 500Uy-IFN alone or in combination. *,
Control; [1, IFN; 0, TNF; 0, TNF & IFN.
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Figure I Viability of AML cells from (a) good responder; and (b) poor responder at day 5 of culture in the presence of
increasing concentrations of TNF/y-IFN. Blast cells from both donors were obtained at presentation. * = <1% viable cells. TNF
dose: OL, 0; E, 20; is, 200; E, 500; *, 2000Uml -.
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Figure 3 Mean (+s.e.) viability of myeloid blasts from all 9
patients at day 7 of culture, alone or treated with 50OUTNF
and 50OUy-IFN alone or in combination. Analysis of variance
showed:
I) No significant effect for addition of TNF alone
2) Highly significant effect for addition of y-IFN alone
(P<0.001)
3) Highly significant effect for combination of y-IFN and TNF
over either agent alone (P<0.0001)
Analysis of variance using pooled within-groups mean square.
Group I =No treatment Group 2=TNF
Group 3 =IFN Group 4=TNF+IFN
Gp vs. Gp T P
I x 2 1.841 0.075
1x3 4.902 <0.001
I x4 9.959 <0.0001
2x3 3.061 0.004
2x4 8.119 <0.001
3 x4 5.057 <0.001
Discussion
Recombinant DNA derived cytokines have now been used as
single agents in the treatment of a wide variety of tumours.
Although some successes have been reported using IL-2 for
solid tumours (Ratain et al., 1985) or x-interferon for
treatment of hairy cell leukaemia (Rosenberg et al., 1985)
and CGL (Talpaz et al., 1985), these agents have generally
proved to have limited effects. In part this has been
attributed to an intrinsic lack of cell susceptibility, but it is
now clear that at least some unresponsive tumours may
simply lack appropriate cytokine receptors (Tsujimoto et al.,
1986; Ruggerio et al., 1986; Lehmann & Droge, 1986). The
observation that y-IFN induces receptors for TNF on both
murine and human tumour cell lines and that the two agents
in combination may have synergistic properties (Tsujimoto et
al., 1986; Ruggiero et al., 1986), led us to test this
combination against a range of fresh leukaemic blasts.
There are two approaches that may be used to evaluate
the effect of cytokines on leukaemic blasts. The first is to
measure their effects on those cells which form colonies in
semi-solid liquid media. This approach has the advantage
that it measures activity on a population of growing cells
which may also represent clonogenic precursors. Using this
technique, Broxmeyer et al. (1986) recently showed that the
combination of TNF and y-IFN was toxic in vitro to these
AML precursor cells, at least in two patients. However, this
approach has the disadvantage that it can only be used to
study leukaemias from which colonies can be grown. It also
detects effects on just one, albeit important, subpopulation
of leukaemic cells. The alternative approach, to add
cytokines directly to cultured blast cells, which we have used
here, has the disadvantage that it measures responses in a
population of declining viability (although in the experiments
described here anti-leukaemic effects are seen within 48h,
when viability of control cultures is >95%), but the
advantages that it can be applied to every leukaemia and
measures the effects on the overall population of cells, rather
than one particular subpopulation. This approach may
therefore more readily expose the biological heterogeneity of
leukaemic cell responses to TNF and y-IFN. The present
results are consistent with those of Broxmeyer et al. (1986)
using the colony assay and suggest that both methods are
valid.
Although the cells from patients with ALL were not
affected directly in vitro, we have shown elsewhere
(Cordingley et al., manuscript in preparation) that this lack
of direct activity in a single in vitro assay may not c- rrelate
with potential therapeutic effects, since co-culture c hairy
cells with TNF and y-IFN leads to a marked increase in the
susceptibility of the hairy cells to natural killer cell activity.
The effects of cytokine combinations in vivo may clearly be
more extensive than results obtained from selected in vitro
systems would suggest.
The combination of y-IFN and TNF has two potential
disadvantages that could preclude clinical use. The first is
that the non-haematological side-effects induced by the
cytokines individually may be potentiated when they are
used together. Mitigating against this is the likelihood that
the synergistic cytotoxicity of y-IFN and TNF would permit
lower total doses of the agents to be administered. The
second is that the agents suppress normal haematopoiesis
(Abboud et al., 1985): this, however, is obviously not a new
problem in leukaemia therapy. Although Broxmeyer et al.
(1986) have confirmed that TNF and y-IFN inhibit normal
haemopoietic progenitors, there is no evidence to suggest
that these agents would prove ablative to pluripotent stem
cells. However, clinical trials will be needed to determine
the relative toxicities of the combination to normal
haematopoiesis or AML. The major predicted advantage of
therapy with cytokine combinations is that their mechanism
of action is distinct from that of conventional
chemotherapeutic agents. Trials of such therapy may
therefore initially be indicated in relapsed or drug-resistant
disease, while ultimately the combination of cytokines with
existing drugs may produce improved rates of disease-free
survival. The present findings strongly suggest that such
trials should initially be carried out in AML rather than
ALL.
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